Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06178614 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-87890387 for Advanced Solid Tumors
A Phase 1 study of Neoplasms and Advanced Solid Tumors, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 6
- Study locations
NCT06178614 is a Phase 1 study of Neoplasms and Advanced Solid Tumors that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 200 participants, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (88% lower). The trial reports 6 study locations across 3 states.
The verdict
NCT06178614, a Phase 1 study of Neoplasms and Advanced Solid Tumors, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to determine safety and recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).
Conditions Studied
Interventions
- DRUG JNJ-87890387
Study Locations (6)
Other
- Centre Leon Berard - Lyon
- Institut Gustave Roussy - Villejuif
- Hosp Univ Vall D Hebron - Barcelona
- Hosp. Univ. 12 de Octubre - Madrid
Michigan
- Start Midwest - Grand Rapids
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-12-14 |
| Est. Completion | 2029-02-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06178614
The ClinicalTrials.gov registry entry for NCT06178614 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (88% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which JNJ-87890387 is the first listed.
NCT06178614 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Other, Michigan, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06178614 about?
NCT06178614 is a clinical study titled "A Study of JNJ-87890387 for Advanced Solid Tumors". The purpose of this study is to determine safety and recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).
What is the current status of trial NCT06178614?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2023-12-14. Estimated completion is 2029-02-07.
What conditions does trial NCT06178614 study?
This clinical trial studies the following conditions: Neoplasms, Advanced Solid Tumors.
What interventions are being tested in trial NCT06178614?
The interventions under investigation include: JNJ-87890387 (DRUG).
Who is sponsoring clinical trial NCT06178614?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06178614 being conducted?
This trial has 6 study locations across Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.